Viridian Therapeutics's market cap is currently ―. The company's EPS TTM is $-5.323; its P/E ratio is -3.29; Viridian Therapeutics is scheduled to report earnings on May 8, 2024, and the estimated EPS forecast is $-1.09. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Income Statement	-
Total Revenue	$ 72.00K	$ 72.00K	-	$ 105.00K	$ 1.20M
Gross Profit	$ 72.00K	$ 72.00K	-	-	-
EBIT	$ -47.06M	$ -54.86M	$ -68.35M	$ -49.07M	$ -28.74M
EBITDA	$ -49.38M	-	$ -71.17M	$ -49.85M	$ -28.68M
Net Income Common Stockholders	$ -47.66M	$ -55.06M	$ -68.15M	$ -20.09M	$ -28.91M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 201.41M	$ 334.29M	$ 373.86M	$ 424.55M	$ 431.32M
Total Assets	$ 328.76M	$ 351.47M	$ 386.64M	$ 435.09M	$ 440.58M
Total Debt	$ 20.00M	$ 4.71M	$ 4.68M	$ 4.64M	$ 5.18M
Net Debt	$ -181.41M	$ -329.58M	$ -369.18M	$ -419.90M	$ -426.14M
Total Liabilities	$ 45.18M	$ 35.61M	$ 36.09M	$ 40.03M	$ 31.57M
Stockholders Equity	$ 283.58M	$ 315.86M	$ 350.55M	$ 395.06M	$ 409.01M
Cash Flow	-
Free Cash Flow	$ -39.39M	-	$ -62.09M	$ -34.27M	$ -20.76M
Operating Cash Flow	$ -38.98M	-	$ -61.97M	$ -34.04M	$ -20.67M
Investing Cash Flow	$ 48.04M	-	$ -13.29M	$ -180.60M	$ 42.65M
Financing Cash Flow	$ 15.46M	-	$ 8.20M	$ 26.01M	$ 290.93M

Currency in USD

Viridian Therapeutics Earnings and Revenue History

Income Statement >

Viridian Therapeutics Debt to Assets

Balance Sheet >

Viridian Therapeutics Cash Flow

Cash Flow >

Viridian Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing